Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00077987
First received: February 13, 2004
Last updated: January 9, 2007
Last verified: October 2005

February 13, 2004
January 9, 2007
December 2003
Not Provided
Anti-tumor efficacy
Not Provided
Complete list of historical versions of study NCT00077987 on ClinicalTrials.gov Archive Site
Tumor control survival safety
Not Provided
Not Provided
Not Provided
 
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab

Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Colorectal Neoplasms
Drug: SU011248
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
84
April 2005
Not Provided

Inclusion Criteria:

  • Metastatic colorectal cancer
  • Failed selected cancer therapies in the past.

Exclusion Criteria:

  • Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than bevacizumab.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00077987
A6181003
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP